Neurocrine Biosciences is joining the M&A bonanza with a $2.9 billion takeover of profitable rare disease drugmaker Soleno Therapeutics. Neurocrine will pay $53 per share,

It’s no secret that cancer drug development is full of bandwagons. Companies see a promising target, and crowd around it (see PD-1xVEGF or HER2 for

Syneron Bio said it raised a Series B round worth $150 million, which it will use to back the development of a drug class that’s

VML Health has published a report about 10 trends defining the future of healthcare, making the case that pharma marketers must adapt to patients shifting

Welcome back to Endpoints Weekly! They say March comes in like a lion and out like a lamb, but two pharma giants made a roar